Connect with us

Top Stories

Johnson & Johnson Covid-19 vaccine produces strong immune response in early trial

A single dose of Johnson & Johnson’s experimental vaccine COVID-19 elicited a strong immune response to the novel coronavirus in an early and intermediate clinical trial, according to interim results released on Friday. The study of nearly 1,000 healthy adults, supported by the US government, began after the discovery of the J&J vaccine in July to provide strong single-dose protection for monkeys. The company said it expects the results of this so-called phase 3 study by the end of the year or early next year.

View Full Article


This news content is a computer generated summarized version of the original article and the authenticity of the original content has not been verified. Please click on the View Article button to refer to the actual content.